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IMMUNOLOGIC AUTOGRAFT ENGINEERING BY MANIPULATION OF
APHERESIS MACHINE COLLECTION SETTINGS
Joao, C.1,2, Porrata, L.F.2, Burgstaler, E.A.2, Nevala, W.2, Uhl, C.2,
Katipamula, R.2, Gastineau, D.A.2, Winters, J.2, Markovic, S.N.2 1.
Portuguese Institute of Oncology, Lisbon, Portugal; 2. Mayo Clinic
College of Medicine, Rochester, MN.
Introduction: Infused autograft absolute lymphocyte count (A-
ALC) is an independent prognostic indicator of survival in patients
undergoing autologous hematopoietic stem cell transplantation
(AHSCT) for non-Hodgkin’s lymphoma (NHL). We previously
demonstrated that different (instrument speciﬁc) apheresis ma-
chine settings calibrated for the purpose of optimal stem cell
collections have a direct impact on A-ALC, which in turn affected
clinical outcome post-AHSCT. Purpose: We present interim re-
sults from an ongoing prospective study in which pheresis settings
of the Baxter Amicus pheresis machine are systematically altered
with the intent of maximal A-ALC collection while preserving
CD34 counts in patients with NHL. Results: To date, we have
available data on 12 patients (5 females). The apheresis settings of
the machines were modiﬁed for one of the apheresis sessions (test)
and compared to a session using conventional settings (control),
using the same patient as his own control. All the patients were
subject to the same stem cell mobilization regimen (Neupogen).
The analysis of the A-ALC was, on average, 2.86 times higher
compared to the control setting (median of 0.40 and 0.14 
109/Kg, respectively, P  .03). Regarding the numbers of lympho-
cyte subsets (CD3, CD4, CD8, CD3/CD16/CD56,
CD20, CD34, CD4/CD45RA, RO, CD8/CD45RA, RO,
and CD4/CD25), the test settings demonstrated graft enrich-
ment 1.6 to 5.7 times relative to control. Table 1 shows the
absolute lymphocyte subsets numbers  109/kg comparing test
versus control settings. All patients engrafted and none developed
side effects during the apheresis procedure. Conclusion: Our
preliminary data suggest that it is feasible to manipulate the
apheresis settings in order to allow a higher A-ALC. The enrich-
ment with naive T cells, memory T cells, and NK cells by manip-
ulating apheresis machine settings may establish a more immuno-
competent autograft to use as an adoptive immunotherapeutic
strategy in AHSCT warrants further studies (Table 1).
Table 1. Autograft Lymphocyte Subset Analysis Comparing
Manipulated (test) vs Control Setting of the Baxter Amicus
Lymphocyte Subset
Test
( 10[9])/kg
Control
( 10[9])/kg
CD3 0.20 0.06
CD4 0.05 0.02
CD8 0.14 0.04
CD16/CD56 0.04 0.02
CD4/CD25 0.20 0.02
CD4/CD45RA 0.014 0.003
CD4/CD45RO 0.019 0.009
CD8/CD45RA 0.048 0.009
CD8/CD45RO 0.007 0.002
CD20 0.044 0.009
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QUANTITATIVELY MONITORING ENGRAFTMENT OF TWO CHILDREN
WITH MIXED UMBILICAL CORD BLOOD TRANSPLANTATION
Chen, D.-P.1, Tseng, C.-P.2, Wang, M.-C.1, Jaing, T.-H.1,
Sun, C.-F.1 1. Chang Gung Memorial Hospital, Taoyuan County,
Taiwan; 2. Chang Gung University, Taoyuan County, Taiwan.
To study the dynamic engraftment during umbilical cord blood
combined transplantation, two children with severe thalassemia
who received two units unrelated umbilical cord blood transplan-
tation were monitored quantitatively by ﬂuorescence labeling poly-
merase chain reaction. The chimeric types of engraftment were
quantitatively evaluated by comparing 15 STR loci of the blood
samples before and after transplantation. The relative level of the
two donors in the engraftment chimerism was determined by
ﬂuorescence scanning of the STR using ABI PRISM 310 DNA
sequencer. Our data revealed that one child with CD34 2.47 
105/kg (donor 1) and CD34 1.75  103/kg (donor 2) transplan-
tation showed a complete one donor type (donor 1) at 14 days after
engraftment. Follow-up survey at 40 days, 66 days, 120 days, and
150 days after transplantation still showed only one donor type,
indicating that the engraftment turned to a single donor type at a
very early stage and sustained in long-term. The other child with
CD34 1.01  105/kg (donor 1) and CD34 1.53  105/kg
(donor 2) transplantation revealed an engraftment chimera consti-
tuted of 7.02% of donor 1 and 92.98% of donor 2 at 16 days after
transplantation. At 45 days after transplantation, the engraftment
chimera constituted of 4.64% of donor 1 and 95.36% of donor 2.
The one with fewer CD34 stem cells was rejected and the one
with more CD34 stem cells was ﬁnally engrafted. This study
implicates that quantitative detection of STR chimera with ﬂuo-
rescence labeling polymerase chain reaction can depict precisely
the engraftment level and the course of umbilical cord blood
combined transplantation. This method thus provides an accurate
and reliable experimental basis for clinical umbilical cord blood
application and donor selection during children transplantation
with mixed umbilical cord blood.
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PEDIATRIC PATIENTS DEMONSTRATE LOW ABSOLUTE PERIPHERAL
BLOOD CD34 CELLS FOR ADEQUATE STEM CELL COLLECTION
Cheerva, A.C.1,2, Breslin, N.1, Monica, H.1, Hubbard, B.1, Renate, W.1
1. Norton Kosair Children’s Hospital, Louisville, KY; 2. University of
Louisville, Louisville, KY.
The peripheral blood CD34 cell concentration was studied as
a guide to the timing of stem cell aphereses in 35 pediatric patients
with various solid tumors and hematologic malignancies. These 35
patients underwent 82 leukaphereses. There was a highly signiﬁ-
cant correlation between the blood CD34 cell count and the
CD34 cell content in the apheresis product of the same day. The
desired yield of 1  106 CD34 cells/kg was harvested in one
apheresis procedure when the blood CD34 cell count was greater
than 9  106 cells/L. An insufﬁcient stem cell harvest was pro-
duced when the blood CD34 cell count was less than 4.5 
106/L. Engraftment of these cells was evaluated and occurred
within 9–17 days in all cases where the apheresis product cells were
utilized. In this pediatric population of patients, the blood CD34
cell count that produces an adequate stem cell collection is lower
than that reported by others. In adult and mostly adult populations,
the CD34 cell count associated with an adequate collection of
peripheral blood CD34 cells is generally reported as greater than
20  106/L. This may reﬂect more brisk mobilization of bone
marrow CD34 cells in the pediatric population versus the adult
patient population. As in other reports, the CD34 cell count is a
good predictor of the CD34 cell content of the apheresis product.
HEMATOPOIESIS/MESENCHYMAL CELLS
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A STROMAL CELL DERIVED FACTOR 1 (SDF-1) AGONIST STIMULATES
NEUTROPHIL MOBILIZATION IN NORMAL HUMANS AFTER SUBCUTA-
NEOUS INJECTION
Wong, D.1, Korz, W.1, Merzouk, A.1, Salari, H.1, Bensinger, W.I.2 1.
Chemokine Therapeutics Corp, Vancouver, BC, Canada; 2. Fred
Hutchinson Cancer Research Center, Seattle, WA.
Stromal cell-derived factor-1 (SDF-1) is key in the proliferation,
homing, engraftment, and expansion of hematopoietic stem cells
and leukocytes. CTCE-0214, a peptide produced by rational drug
design, is an analog of SDF-1 and agonist of the SDF-1 receptor,
CXCR4. In vitro and in vivo models have shown that CTCE-0214
mobilized blood and progenitor cells and enhanced the survival
and expansion of cord blood cells (Letters in Drug Design and
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Discovery. 1:126, 2004; Exp Hematol. 32:470, 2004; Exp Hematol.
32:300, 2004; Stem Cells. In press). In this ﬁrst phase I clinical trial
of CTCE-0214, the safety, tolerability, pharmacokinetic proﬁle,
and the pharmacodynamic effects of single subcutaneous doses of
CTCE-0214 given to healthy subjects were studied. The random-
ized, double-blinded, placebo-controlled dose-escalation trial en-
rolled 24 subjects in 6 dose-escalation groups. Four healthy human
subjects in each cohort received either CTCE-0214 or Placebo,
randomized in a 3:1 ratio. The doses of CTCE-0214 were 0.2
mg/kg, 0.5 mg/kg, 0.8 mg/kg, 1.5 mg/kg, 2.0 mg/kg, and 3.0
mg/kg. CTCE-0214 was shown to be safe with no serious adverse
events reported. The most common drug related adverse events
were injection site pain and erythema, which were transient and
resolved without intervention. The severity of injection site pain
appeared to be associated with the overall quantity of study drug
administered. Moderate or severe pain was reported only at 80 mg
or greater of CTCE-0214 per syringe. Dilution across more than
one syringe appeared to effectively reduce injection site pain.
Pharmacokinetic analysis of CTCE-0214 plasma concentrations
showed that Tmax was reached at 0.25 hours post-administration
for all CTCE-0214 treated cohorts. The apparent terminal elim-
ination half-life (t1/2) values were estimated to be 0.41 to 0.32
hours. CTCE-0214 administration was associated with signiﬁcant
dose-dependent increases in total white blood cell and neutrophil
counts in treated subjects, peaking at around 6 hours post-injec-
tion. In the 3.0 mg/kg arm, the mean difference in neutrophil
count from baseline was more than three times that of the Placebo
arm. The same trend was apparent in the 2.0 and 1.5 mg/kg arms.
These results suggest that SDF-1 agonists may potentially be used
in patients with low neutrophil count receiving chemotherapy with
or without the use of G-CSF. The potential for CTCE-0214 to
mobilize neutrophils and other blood cells merits serious consid-
eration.
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DYSKERATOSIS CONGENITA: A HUMAN MODEL TO STUDY THE ROLE
OF TELOMERASE AND TELOMERE LENGTH IN HEMATOPOIESIS
Goldman, F.D.1, Cooper, S.R.1, Singhal, V.1, Klingelhutz, A.2,
Lansdorp, P.3, Schlueter, A.4 1. University of Iowa Children’s Hospital;
2. University Iowa, Department of Microbiology; 3. University of British
Columbia, Department of Medicine; 4. University of Iowa, Department
of Pathology.
Dyskeratosis congenita (DC) is an inherited multisystem disorder
of premature aging characterized by early bone marrow (BM)
failure. This disease is due to telomerase defects resulting in telo-
mere shortening and premature senescence of various somatic
cells, particularly those from highly proliferative tissues. Telomer-
ase plays an important though not fully understood role in hema-
topoiesis. We have recently identiﬁed a three-generation kindred
with autosomal dominant DC with affected individuals having a
single gene deletion of the RNA component of telomerase,
hTERC, and recent third generation patients are displaying signs
of BM dysfunction at an earlier age than their affected parents. To
explain these ﬁndings, we hypothesize that early BM failure in DC
may be due to a proliferative/differentiative defect in hematopoi-
etic stem cells (HSC) as a consequence of telomere shortening.
Five patients (age 11–50) from 2 successive generations have thus
far been enrolled on a study that allows collection of HSC by
leukopheresis. All patients had clinical and laboratory features of
DC, including signiﬁcant BM hypocellularity (10–30%). The per-
centage of CD34 cells in the G-CSF primed leukopheresis prod-
uct was signiﬁcantly lower in DC subjects (0.05–0.24%) compared
to controls (0.7–1.2%). Extensive immunophenotyping of HSC
revealed a higher percentage of CD33/CD34 cells in DC
subjects (60–97%) relative to controls (9–28%). HSC function was
examined in vitro by a clonogenic progenitor cell assay, assessing
percent, number, and morphology of colony forming units (CFU).
Of note, 2/5 DC subjects (both third generation) had a markedly
reduced number of CFU, and percentage of CFU-GM and CFU-
GEMM were decreased in 4/5 DC subjects relative to controls. To
assess DC HSC function in vivo, CD34 HSC from 2 different
DC subjects and age-matched controls were injected into suble-
thally irradiated NOD-SCID mice. None of the mice injected with
DC HSC showed evidence of human hematopoiesis at up to 20
weeks post injection, while animals receiving control HSC had
evidence of human hematopoiesis by 6 weeks. In conclusion, DC is
an excellent human model to assess the role of telomerase and
telomere shortening in hematopoiesis. Importantly, there appears
to be a correlation of the DC clinical phenotype and DC HSC
function with telomere length. Further studies are needed to de-
termine whether the aberrant function of DC HSC can be rescued
by a gene-transfer approach.
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GLYCOGEN SYNTHASE KINASE-3 IS AN IN VIVO REGULATOR OF HU-
MAN HEMOPOIETIC STEM CELLS
Trowbridge, J.J.1, Xenocostas, A.2, Moon, R.T.3, Bhatia, M.1 1. Krem-
bil Centre for Stem Cell Biology, Robarts Research Institute, London,
ON, Canada; 2. London Health Sciences Centre & The University of
Western Ontario, London, ON, Canada; 3. Howard Hughes Medical
Institute & The University of Washington School of Medicine, Seattle,
WA.
Hemopoietic stem cells (HSCs) are rare cells of the hemopoietic
system with the ability to self-renew and differentiate into mature
blood cells. The application of HSC transplantation as a curative
intervention can be limited by the lack of a suitable donor or the
suboptimal collection of HSCs. Umbilical cord blood (UCB) cells
have potential as a readily available alternate source of HSCs but at
present have limited utility in adult recipients because the relatively
low numbers of HSCs can lead to delayed hemopoietic reconsti-
tution. At present, there exists no therapeutic intervention that
allows for the in vivo expansion of transplanted HSCs. We exam-
ined the effects of inhibiting glycogen synthase kinase-3 (GSK-3),
a constitutively active serine/threonine kinase, on the regulation of
the human HSC pool. Primitive lineage-depleted (Lin-) neonatal
UCB cells or adult G-CSF mobilized peripheral blood (M-PB)
cells were intravenously injected into sublethally irradiated NOD/
SCID mice. The mice were then treated with either 30 mg/kg of
a GSK-3 inhibitor or with vehicle twice per week for the duration
of the 5 to 6 week transplant period. NOD/SCID recipients
treated with the GSK-3 inhibitor demonstrated an increased fre-
quency and total number of primitive human HSCs (CD45
CD34) after transplantation of UCB-derived HSCs compared to
vehicle-treated controls. The mean number of HSCs in the bone
marrow were 12791  2892 versus 62374  15533, respectively,
(mean  SEM; P  .02; N  4 mice/group). To further charac-
terize the effect of GSK-3 inhibition on human HSC repopulating
capacity, sorted CD45 human hematopoietic cells from the re-
constituted mice were plated in a functional clonogenic in vitro
assay. Hemopoietic cells derived from recipients reconstituted with
UCB or M-PB-HSCs and treated with GSK-3 inhibitor generated
greater numbers of HSC-colony forming units (HSC-CFU) than
untreated controls (mean  SEM: 2121  526 versus 1021  356;
respectively. P .038, N 7). The developmental potential of the
HSC-CFU to form mature colonies of various subtypes (erythroid,
granulocyte, macrophage, and granulocyte-macrophage) was not
altered by the treatment. Our results demonstrate that GSK-3 can
modulate HSC activity in vivo and suggest that administration of
GSK-3 inhibitor may provide a clinical means to directly enhance
the repopulating capacity of transplanted HSCs.
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MULTIPOTENT ADULT PROGENITOR CELLS (MAPC) ARE NON-IMMU-
NOGENIC AND DISPLAY IMMUNOSUPPRESSIVE PROPERTIES ON ACTI-
VATED T CELLS
Kovacsovics-Bankowski, M.1, Streeter, P.R.1, Van’t Hof, W.J.2,
Deans, R.J.2, Maziarz, R.T.1 1. OHSU, Portland, OR; 2. Athersys,
Cleveland, OH.
Multipotent Adult Progenitor cells (MAPC) are nonhematopoi-
etic stem cells, present within the bone marrow that can be grown
extensively and can be induced to generate cells with phenotypic
characteristics and gene proﬁle of cells derived from endoderm,
ectoderm and mesoderm. The capacity to differentiate into these
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